سعر نو-ميجران زد 2.5مجم 2 قرص 2022

No-migrain Z 2.5 mg 2 film-coated tablets (Amoun, Egypt): zolmitriptan 2.5 mg oral film-coated tablets, a selective 5-HT1B/1D receptor agonist for acute migraine; pack of 2 tablets.

• Acute treatment of migraine with or without aura in adults; use only after a clear diagnosis of migraine. Not indicated for prevention of migraine or for cluster headache.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (5% or more and greater than placebo): neck/throat/jaw pain, tightness or pressure; dizziness; paraesthesia; asthenia; somnolence; warm/cold sensation; nausea; heaviness sensation; dry mouth.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Ischaemic coronary artery disease, other significant cardiovascular disease or coronary vasospasm (including Prinzmetal's angina); Wolff-Parkinson-White syndrome or accessory pathway arrhythmias.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• History of stroke, TIA, or hemiplegic or basilar migraine; peripheral vascular disease; ischaemic bowel disease; uncontrolled hypertension.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Use within 24 hours of another 5-HT1 agonist or an ergotamine-containing or ergot-type medication; concurrent MAO-A inhibitor use or use within 2 weeks of stopping it; hypersensitivity.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Myocardial ischaemia, infarction and Prinzmetal's angina: evaluate cardiovascular status in triptan-naive patients with multiple risk factors before use.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Arrhythmias; chest, throat, neck or jaw pain/tightness/pressure; cerebrovascular events; other vasospasm reactions; increase in blood pressure.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Medication overuse headache with overuse of acute migraine drugs; serotonin syndrome, particularly with SSRIs/SNRIs.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Ergot-containing drugs (ergotamine, dihydroergotamine, methysergide)Additive prolonged vasospastic reactions; use within 24 hours of each other is contraindicated.DailyMed (U.S. National Library of Medicine)
• MAO-A inhibitorsIncrease systemic exposure to zolmitriptan and its active metabolite; use is contraindicated.DailyMed (U.S. National Library of Medicine)
• Other 5-HT1B/1D agonists (triptans)Use within 24 hours is contraindicated (additive vasospastic risk).DailyMed (U.S. National Library of Medicine)

• No adequate data on developmental risk in pregnant women; in rats and rabbits zolmitriptan caused embryolethality and fetal abnormalities at clinically relevant exposures; women with migraine may be at increased risk of pre-eclampsia.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; in rats milk levels were up to 4 times maternal plasma levels; weigh breastfeeding benefits against the mother's need.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Zolmitriptan: Selective agonist at serotonin 5-HT1B/1D receptors (triptan).